Now poised for a speedy trip through the FDA’s regulatory review, Roche’s oral challenger in spinal muscular atrophy (SMA) could soon pick up a nod …
Routine access to Spinraza® (nusinersen) for type 1 spinal muscular atrophy granted, with discussions continuing to secure access for other forms of the disease The …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
